Schering-Plough Corporation (NYSE: SGP) today announced that the Peg-Intron® pre-filled pen (peginterferon alfa-2b) Single-dose Delivery System for the treatment of hepatitis C is being launched in Europe.
The introduction of the Peg-Intron pre-filled pen marks a major advancement in helping patients manage their disease. Each pre-filled pen Single-dose Delivery System will contain Peg-Intron at one of five different dosing strengths for a single use — 50 mcg, 80 mcg, 100 mcg, 120 mcg or 150 mcg. Maximum injection volume is 0.5 ml delivered through a very fine 30-gauge needle specifically designed to reduce patient discomfort often associated with needles utilized for subcutaneous injection.
“Schering-Plough is dedicated to providing innovative treatment options to patients with hepatitis C,” said Roch Doliveux, president of Schering-Plough International. “We are very pleased to offer patients in Europe the Peg-Intron pre-filled pen, which offers a convenient method for administering Peg-Intron. This may help patients adhere to their treatment regimens.”
תגובות רוצה להצטרף לדיון?
יש להתחבר כדי להגיב.
התחבראין תגובות עדיין. היה הראשון להגיב!